Clinuvel Pharmaceuticals (HAM:UR9) Moat Score: 5/10 (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:UR9 Clinuvel Pharmaceuticals Ltd HAM:UR9
80 GF Score
Price €6.00
GF Value €10.76
! 2 Warning Signs
View Full Analysis

What is Clinuvel Pharmaceuticals Moat Score?

Clinuvel Pharmaceuticals HAM:UR9 -1.12% 80 Moat Score is 5 as of Jul. 19, 2026. GuruFocus rates HAM:UR9 with a GF Score™ of 80/100 and a GF Value™ of €10.76. The stock has 2 warning signs investors should review. Among 1,396 Biotechnology companies, Clinuvel Pharmaceuticals ranks better than 96.7% on this metric.

Clinuvel Pharmaceuticals has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Clinuvel Pharmaceuticals has Narrow Moat: Clinuvel Pharmaceuticals benefits from valuable intellectual property and patents in niche medical treatments, providing a solid narrow moat. However, it faces challenges in scaling and lacks significant network effects.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Clinuvel Pharmaceuticals might have Narrow Moat - Solid narrow moat.

Clinuvel Pharmaceuticals  (HAM:UR9) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Clinuvel Pharmaceuticals Moat Score Related Terms

HAM:UR9 vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clinuvel Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Moat Score falls into.


HAM:UR9
80GF Score
Clinuvel Pharmaceuticals Ltd HAM:UR9
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Clinuvel Pharmaceuticals (HAM:UR9) has a Moat Score of 5 as of Jul. 19, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Clinuvel Pharmaceuticals ranks #46 out of 1396 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Clinuvel Pharmaceuticals' Moat Score too high?
Clinuvel Pharmaceuticals' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Clinuvel Pharmaceuticals' value of 5 is 150% above this industry median. Based on the distribution chart, Clinuvel Pharmaceuticals ranks #46 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clinuvel Pharmaceuticals has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Clinuvel Pharmaceuticals' Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clinuvel Pharmaceuticals ranks #46 out of 1396 companies for Moat Score. This places Clinuvel Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Clinuvel Pharmaceuticals' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clinuvel Pharmaceuticals's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinuvel Pharmaceuticals's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinuvel Pharmaceuticals stock overvalued right now?
Clinuvel Pharmaceuticals (HAM:UR9) has a current Moat Score of 5. The stock's GF Value™ is €10.76, compared to a current price of €6.00 — trading 44.2% below its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Clinuvel Pharmaceuticals' overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Clinuvel Pharmaceuticals (HAM:UR9), the current Moat Score is 5 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Clinuvel Pharmaceuticals (HAM:UR9) Overvalued in 2026?

Based on GuruFocus' analysis, Clinuvel Pharmaceuticals stock appears to be undervalued. The current stock price of €6.00 is trading 44.2% below its estimated GF Value™ of €10.76.

Key valuation signals for HAM:UR9:

  • Moat Score: 5
  • GF Value™: €10.76 vs. price of €6.00 (44.2% below fair value)
  • GF Score™: 80/100 with 2 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1396)

No single metric tells the full story. See the HAM:UR9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Clinuvel Pharmaceuticals Business Description

Address 535 Bourke Street, Level 22, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.
80GF Score

Get the complete analysis for HAM:UR9

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.00
Price
€10.76
GF Value